Chimeric antigen receptor transduced T cells

• Verfasst von: Schubert, Maria-Luisa [VerfasserIn]
• Verfasst von: Hoffmann, Jean-Marc [VerfasserIn]
• Verfasst von: Dreger, Peter [VerfasserIn]
• Verfasst von: Müller-Tidow, Carsten [VerfasserIn]
• Verfasst von: Schmitt, Michael [VerfasserIn]
• Titel: Chimeric antigen receptor transduced T cells
• Titelzusatz: tuning up for the next generation
• Verf.angabe: Maria-Luisa Schubert, Jean-Marc Hoffmann, Peter Dreger, Carsten Müller-Tidow and Michael Schmitt
• Jahr des Originals: 2017
• Umfang: 10 S.
• Fussnoten: Published online: 9 Nov 2017 ; Gesehen am 13.04.2018
• Titel Quelle: Enthalten in: International journal of cancer
• Jahr Quelle: 2018
• Band/Heft Quelle: 142(2018), 9, S. 1738-1747
• ISSN Quelle: 1097-0215
• DOI: doi:10.1002/ijc.31147
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1571997113

Abstract

Chimeric antigen receptor (CAR) T cell therapy has recently achieved impressive clinical outcome in patients with CD19?positive hematologic malignancies. Extrapolation of CAR T cell treatment to solid tumors, however, has not yet yielded similar results. This might be due to intrinsic causes, e.g. insufficient CAR T cell activation or CAR toxicity as well as extrinsic factors displaying an unfavorable tumor environment for CAR T cells by raising physical and chemical barriers. In this review, we discuss the advantages as well as major obstacles of CAR T cell therapy, particularly in the context of solid tumors, and focus on efforts and novel strategies in CAR T cell development.